| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Mar, 2025 | Mar, 2025 | Mar, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -11,980 | -7,060 | 0 | 0 | 0 |
| Net Income Growth | -69.69% | unch | unch | unch | unch |
Mira Pharmaceuticals Inc (MIRA)
1.0800 x 13 1.1000 x 33
Post-market by (Cboe BZX)
1.0600 -0.0400 (-3.64%) 03/28/25 [NASDAQ]
1.0800 x 13 1.1000 x 33
Post-market 1.0500 -0.0100 (-0.94%) 16:06 ET
for Fri, Mar 28th, 2025
MIRA Pharmaceuticals Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA Pharmaceuticals Inc. is based in Baltimore, Maryland.
Fiscal Year End Date: 12/31